CN103936763B - 噁唑烷酮类化合物及其制备方法和用途 - Google Patents

噁唑烷酮类化合物及其制备方法和用途 Download PDF

Info

Publication number
CN103936763B
CN103936763B CN201310020040.8A CN201310020040A CN103936763B CN 103936763 B CN103936763 B CN 103936763B CN 201310020040 A CN201310020040 A CN 201310020040A CN 103936763 B CN103936763 B CN 103936763B
Authority
CN
China
Prior art keywords
compound
room temperature
mmol
hours
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310020040.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103936763A (zh
Inventor
杨玉社
薛涛
丁实
郭彬
李战
李炜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica
Nanjing Changao Pharmaceutical Science and Technology Co Ltd
Original Assignee
Shanghai Institute of Materia Medica
Nanjing Changao Pharmaceutical Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201310020040.8A priority Critical patent/CN103936763B/zh
Application filed by Shanghai Institute of Materia Medica, Nanjing Changao Pharmaceutical Science and Technology Co Ltd filed Critical Shanghai Institute of Materia Medica
Priority to JP2015552988A priority patent/JP6242915B2/ja
Priority to CA2898550A priority patent/CA2898550C/en
Priority to AU2013373885A priority patent/AU2013373885B2/en
Priority to EP13872046.1A priority patent/EP2947085B1/en
Priority to US14/761,843 priority patent/US9382265B2/en
Priority to KR1020157021881A priority patent/KR101756570B1/ko
Priority to PCT/CN2013/090833 priority patent/WO2014110971A1/zh
Publication of CN103936763A publication Critical patent/CN103936763A/zh
Application granted granted Critical
Publication of CN103936763B publication Critical patent/CN103936763B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201310020040.8A 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途 Active CN103936763B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201310020040.8A CN103936763B (zh) 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途
CA2898550A CA2898550C (en) 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof
AU2013373885A AU2013373885B2 (en) 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof
EP13872046.1A EP2947085B1 (en) 2013-01-18 2013-12-30 Oxazolidone compounds, method for preparing and application thereof
JP2015552988A JP6242915B2 (ja) 2013-01-18 2013-12-30 オキサゾリジノン系化合物およびその製造方法と使用
US14/761,843 US9382265B2 (en) 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof
KR1020157021881A KR101756570B1 (ko) 2013-01-18 2013-12-30 옥사졸리돈계 화합물 및 이의 제조방법과 용도
PCT/CN2013/090833 WO2014110971A1 (zh) 2013-01-18 2013-12-30 噁唑烷酮类化合物及其制备方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310020040.8A CN103936763B (zh) 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN103936763A CN103936763A (zh) 2014-07-23
CN103936763B true CN103936763B (zh) 2017-10-31

Family

ID=51184670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310020040.8A Active CN103936763B (zh) 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途

Country Status (8)

Country Link
US (1) US9382265B2 (cg-RX-API-DMAC10.html)
EP (1) EP2947085B1 (cg-RX-API-DMAC10.html)
JP (1) JP6242915B2 (cg-RX-API-DMAC10.html)
KR (1) KR101756570B1 (cg-RX-API-DMAC10.html)
CN (1) CN103936763B (cg-RX-API-DMAC10.html)
AU (1) AU2013373885B2 (cg-RX-API-DMAC10.html)
CA (1) CA2898550C (cg-RX-API-DMAC10.html)
WO (1) WO2014110971A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015043364A1 (zh) * 2013-09-29 2015-04-02 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
CN104804017B (zh) * 2014-01-24 2017-11-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
WO2015176677A1 (en) * 2014-05-22 2015-11-26 Sunshine Lake Pharma Co., Ltd. Crystalline forms and amorphism of oxazolidinone compound
CN105693746B (zh) * 2014-06-14 2018-09-14 广东东阳光药业有限公司 噁唑烷酮类化合物的制备方法及其中间体
CN105503903B (zh) * 2014-09-26 2019-04-26 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物的制备方法及其中间体和晶型
CN104672236B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104610260B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610258B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN106478661A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法
CN106478658A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型d及其制备方法
CN105348275A (zh) * 2015-12-10 2016-02-24 中国药科大学 噁唑烷酮类化合物及其合成方法与医药应用
CN108069983A (zh) * 2016-11-10 2018-05-25 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型及其制备方法和应用
CN108395442A (zh) * 2017-02-07 2018-08-14 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型vii及其制备方法和应用
CN108727406B (zh) 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
CN108912142B (zh) * 2018-08-08 2021-06-18 延边大学 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途
CN114685529A (zh) * 2020-12-29 2022-07-01 中国科学院上海药物研究所 噁唑烷酮类化合物的无定形物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260277A (zh) * 2010-05-24 2011-11-30 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN102325528A (zh) * 2008-12-19 2012-01-18 第一三共株式会社 活化凝血因子X(FXa)抑制剂
CN102464658A (zh) * 2010-11-03 2012-05-23 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805117A1 (de) * 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325528A (zh) * 2008-12-19 2012-01-18 第一三共株式会社 活化凝血因子X(FXa)抑制剂
CN102260277A (zh) * 2010-05-24 2011-11-30 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN102464658A (zh) * 2010-11-03 2012-05-23 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clinical and pharmacological properties of new oral anticoagulants for the prevention of cerebral thromboembolism: Factor Xa and thrombin inhibitors;Yaroslav Winter,等;《World Journal of Neuroscience》;20120229;第2卷(第1期);7-14 *
Design, Synthesis, and Structure Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents;Qisheng Xin, 等;《Journal of Medicinal Chemistry》;20110928;第54卷(第21期);7493-7502 *
Design, Synthesis, and Structure−Activity and Structure−Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor;Tao Xue, 等;《Journal of Medicinal Chemistry》;20140902;第57卷(第18期);7770-7791,表2-3 *

Also Published As

Publication number Publication date
CN103936763A (zh) 2014-07-23
US20150361091A1 (en) 2015-12-17
EP2947085A4 (en) 2016-06-22
EP2947085B1 (en) 2017-09-13
JP2016513076A (ja) 2016-05-12
CA2898550C (en) 2016-08-02
KR101756570B1 (ko) 2017-07-10
US9382265B2 (en) 2016-07-05
CA2898550A1 (en) 2014-07-24
EP2947085A1 (en) 2015-11-25
JP6242915B2 (ja) 2017-12-06
AU2013373885A1 (en) 2015-08-27
KR20150105466A (ko) 2015-09-16
AU2013373885B2 (en) 2016-07-14
WO2014110971A1 (zh) 2014-07-24

Similar Documents

Publication Publication Date Title
CN103936763A (zh) 噁唑烷酮类化合物及其制备方法和用途
KR101047211B1 (ko) 인자 xa 억제제로서의 신규 사이클로알케인카복스아마이드
EP2373634B1 (en) Morpholinone compounds as factor ixa inhibitors
US8987242B2 (en) Morpholinone compounds as factor IXA inhibitors
TW201722918A (zh) 作為因子xia抑制劑之經取代四氫異喹啉化合物
CN114591212B (zh) 人类血浆激肽释放酶抑制剂
WO2000044726A1 (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
KR20140040774A (ko) 이미다조피리딘 화합물
EP2473491B1 (en) Morpholinone compounds as factor ixa inhibitors
TW202222770A (zh) 苄胺或苄醇衍生物及其用途
RU2709810C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[3,4-с]ПИРИДИНА
JP6203257B2 (ja) 新規の抗繊維素溶解化合物
EA003426B1 (ru) Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
CN105218564A (zh) 三环噁唑烷酮类化合物及其制备方法和用途
CN104804017B (zh) 噁唑烷酮类化合物及其在药物中的应用
CN115066417B (zh) 凝血因子XIa抑制剂
JPS63225354A (ja) アゼチジノン誘導体
WO2020119590A1 (zh) 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途
CN110759901A (zh) 四氢异喹啉类衍生物及其制备方法和用途
CN110343089A (zh) 苯并咪唑类衍生物及其药学用途
CN105753855A (zh) 含吡咯酰胺的噁唑烷酮类化合物及其应用
CN102199150A (zh) 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途
AU2007308197A1 (en) Novel heteroaryl carboxamides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Yang Yushe

Inventor after: Xue Tao

Inventor after: Ding Shi

Inventor after: Guo Bin

Inventor after: Li Zhan

Inventor after: Li Wei

Inventor before: Yang Yushe

Inventor before: Xue Tao

Inventor before: Ding Shi

Inventor before: Guo Bin

Inventor before: Li Zhan

Inventor before: Li Wei

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant